Literature DB >> 24827414

Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance.

Faisal Rasheed1, Barry James Campbell, Hanafiah Alfizah, Andrea Varro, Rabaab Zahra, Yoshio Yamaoka, David Mark Pritchard.   

Abstract

BACKGROUND: Antibiotic resistance in Helicobacter pylori contributes to failure in eradicating the infection and is most often due to point and missense mutations in a few key genes.
METHODS: The antibiotic susceptibility profiles of H. pylori isolates from 46 Pakistani patients were determined by Etest. Resistance and pathogenicity genes were amplified, and sequences were analyzed to determine the presence of mutations.
RESULTS: A high percentage of isolates (73.9%) were resistant to metronidazole (MTZ), with considerable resistance to clarithromycin (CLR; 47.8%) and amoxicillin (AML; 54.3%) also observed. Relatively few isolates were resistant to tetracycline (TET; 4.3%) or to ciprofloxacin (CIP; 13%). However, most isolates (n = 43) exhibited resistance to one or more antibiotics. MTZ-resistant isolates contained missense mutations in oxygen-independent NADPH nitroreductase (RdxA; 8 mutations found) and NADH flavin oxidoreductase (FrxA; 4 mutations found). In the 23S rRNA gene, responsible for CLR resistance, a new point mutation (A2181G) and 4 previously reported mutations were identified. Pathogenicity genes cagA, dupA, and vacA s1a/m1 were detected frequently in isolates which were also found to be resistant to MTZ, CLR, and AML. A high percentage of CagA and VacA seropositivity was also observed in these patients. Phylogenetic analysis of partial sequences showed uniform distribution of the 3' region of cagA throughout the tree.
CONCLUSIONS: We have identified H. pylori isolates in Pakistan which harbor pathogenicity genes and worrying antibiotic resistance profiles as a result of having acquired multiple point and missense mutations. H. pylori eradication regimens should therefore be reevaluated in this setting.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  23S rRNA gene; Helicobacter pylori infection; antibiotic resistance; cagA; clarithromycin resistance; metronidazole resistance

Mesh:

Substances:

Year:  2014        PMID: 24827414      PMCID: PMC4162849          DOI: 10.1111/hel.12142

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  69 in total

1.  Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori.

Authors:  J Y Jeong; A K Mukhopadhyay; D Dailidiene; Y Wang; B Velapatiño; R H Gilman; A J Parkinson; G B Nair; B C Wong; S K Lam; R Mistry; I Segal; Y Yuan; H Gao; T Alarcon; M L Brea; Y Ito; D Kersulyte; H K Lee; Y Gong; A Goodwin; P S Hoffman; D E Berg
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

Review 2.  Is the molecular basis of metronidazole resistance in microaerophilic organisms understood?

Authors:  George L Mendz; Francis Mégraud
Journal:  Trends Microbiol       Date:  2002-08       Impact factor: 17.079

Review 3.  Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis.

Authors:  Joon Sung Kim; Jeong-Seon Ji; Hwang Choi; Joo Hyun Kim
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-11-12       Impact factor: 2.947

4.  Distribution of Helicobacter pylori cagA, cagE, oipA and vacA in different major ethnic groups in Tehran, Iran.

Authors:  Hossein Dabiri; Parviz Maleknejad; Yoshio Yamaoka; Mohammad M Feizabadi; Fereshteh Jafari; Maryam Rezadehbashi; Farrokh A Nakhjavani; Akbar Mirsalehian; Mohammad R Zali
Journal:  J Gastroenterol Hepatol       Date:  2009-08       Impact factor: 4.029

5.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 6.  Helicobacter pylori persistence: biology and disease.

Authors:  Martin J Blaser; John C Atherton
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

7.  dupA as a risk determinant in Helicobacter pylori infection.

Authors:  Masoumeh Douraghi; Marjan Mohammadi; Akbar Oghalaie; Afshin Abdirad; Mohammad Ali Mohagheghi; Mahmoud Eshagh Hosseini; Hojat Zeraati; Amir Ghasemi; Maryam Esmaieli; Nazanin Mohajerani
Journal:  J Med Microbiol       Date:  2008-05       Impact factor: 2.472

8.  Distinctiveness of the cagA genotype in children and adults with peptic symptoms in South China.

Authors:  Juan Li; Zhiying Ou; Fangjin Wang; Yu Guo; Ren Zhang; Jun Zhang; Peiqiong Li; Weijie Xu; Yunshao He
Journal:  Helicobacter       Date:  2009-08       Impact factor: 5.753

9.  Tetracycline resistance in Chilean clinical isolates of Helicobacter pylori.

Authors:  Héctor Toledo; Remigio López-Solís
Journal:  J Antimicrob Chemother       Date:  2009-12-24       Impact factor: 5.790

10.  Virulence attributes of Helicobacter pylori isolates & their association with gastroduodenal disease.

Authors:  A Saxena; S Shukla; K N Prasad; U C Ghoshal
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

View more
  20 in total

Review 1.  Pathogenesis of Helicobacter pylori Infection.

Authors:  Dionyssios N Sgouras; Tran Thi Huyen Trang; Yoshio Yamaoka
Journal:  Helicobacter       Date:  2015-09       Impact factor: 5.753

2.  Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing.

Authors:  William R Jacobs; Wendy A Szymczak; Rajagopalan Saranathan; Michael H Levi; Alice R Wattam; Adel Malek; Emmanuel Asare; Daniel S Behin; Debra H Pan
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

3.  Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.

Authors:  Mohsen Karbalaei; Amin Talebi Bezmin Abadi; Masoud Keikha
Journal:  BMC Infect Dis       Date:  2022-06-25       Impact factor: 3.667

4.  Syzygium aromaticum L.: Traditional herbal medicine against cagA and vacA toxin genes-producing drug resistant Helicobacter pylori.

Authors:  Wagih A El-Shouny; Sameh S Ali; Hegazy M Hegazy; Manar K Abd Elnabi; Asmaa Ali; Jianzhong Sun
Journal:  J Tradit Complement Med       Date:  2019-05-15

Review 5.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

6.  Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.

Authors:  Muhammad Miftahussurur; Pradeep Krishna Shrestha; Phawinee Subsomwong; Rabi Prakash Sharma; Yoshio Yamaoka
Journal:  BMC Microbiol       Date:  2016-11-04       Impact factor: 3.605

7.  Two populations of less-virulent Helicobacter pylori genotypes in Bangladesh.

Authors:  Hafeza Aftab; Muhammad Miftahussurur; Phawinee Subsomwong; Faruque Ahmed; A K Azad Khan; Takashi Matsumoto; Rumiko Suzuki; Yoshio Yamaoka
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

8.  Screening of E. coli β-clamp Inhibitors Revealed that Few Inhibit Helicobacter pylori More Effectively: Structural and Functional Characterization.

Authors:  Preeti Pandey; Vijay Verma; Suman Kumar Dhar; Samudrala Gourinath
Journal:  Antibiotics (Basel)       Date:  2018-01-11

Review 9.  Relationship between vacA Types and Development of Gastroduodenal Diseases.

Authors:  Tran Thi Huyen Trang; Tran Thanh Binh; Yoshio Yamaoka
Journal:  Toxins (Basel)       Date:  2016-06-09       Impact factor: 4.546

10.  Prevalence of CagA and antimicrobial sensitivity of H. pylori isolates of patients with gastric cancer in Egypt.

Authors:  Doaa M Al-Eraky; Omneya M Helmy; Yasser M Ragab; Zeinab Abdul-Khalek; Eman A El-Seidi; Mohammed A Ramadan
Journal:  Infect Agent Cancer       Date:  2018-07-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.